I Tepler

1.4k total citations
19 papers, 1.1k citations indexed

About

I Tepler is a scholar working on Oncology, Hematology and Epidemiology. According to data from OpenAlex, I Tepler has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Hematology and 4 papers in Epidemiology. Recurrent topics in I Tepler's work include Hematopoietic Stem Cell Transplantation (8 papers), Cancer Treatment and Pharmacology (4 papers) and Neutropenia and Cancer Infections (4 papers). I Tepler is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), Cancer Treatment and Pharmacology (4 papers) and Neutropenia and Cancer Infections (4 papers). I Tepler collaborates with scholars based in United States and United Kingdom. I Tepler's co-authors include Rosemary Mazanet, Gary N. Schwartz, Lois Ayash, Catherine Wheeler, Philip Leder, C Lynch, Larry Norton, Maria Theodoulou, Violante E. Currie and Andrew D. Seidman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

I Tepler

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I Tepler United States 11 681 332 217 189 151 19 1.1k
Anna Novarino Italy 19 577 0.8× 197 0.6× 294 1.4× 174 0.9× 111 0.7× 43 1.1k
Mark A. Arnesen United States 11 445 0.7× 231 0.7× 235 1.1× 60 0.3× 172 1.1× 12 1.2k
M. Luisa Paccagnella United States 13 857 1.3× 439 1.3× 409 1.9× 210 1.1× 275 1.8× 22 1.7k
Manfred Hensel Germany 21 490 0.7× 310 0.9× 188 0.9× 79 0.4× 149 1.0× 68 1.6k
Monica Astolfi Italy 17 526 0.8× 588 1.8× 363 1.7× 74 0.4× 76 0.5× 36 1.2k
Diane C. Louie United States 19 944 1.4× 142 0.4× 398 1.8× 166 0.9× 119 0.8× 24 2.0k
C. Faul Germany 19 308 0.5× 396 1.2× 140 0.6× 138 0.7× 187 1.2× 67 1.4k
PM Kluin Netherlands 9 355 0.5× 209 0.6× 254 1.2× 109 0.6× 50 0.3× 15 973
Rosemary Mazanet United States 12 433 0.6× 293 0.9× 141 0.6× 69 0.4× 187 1.2× 29 741
Martin D. Phillips United States 12 349 0.5× 192 0.6× 153 0.7× 66 0.3× 275 1.8× 16 978

Countries citing papers authored by I Tepler

Since Specialization
Citations

This map shows the geographic impact of I Tepler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I Tepler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I Tepler more than expected).

Fields of papers citing papers by I Tepler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I Tepler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I Tepler. The network helps show where I Tepler may publish in the future.

Co-authorship network of co-authors of I Tepler

This figure shows the co-authorship network connecting the top 25 collaborators of I Tepler. A scholar is included among the top collaborators of I Tepler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I Tepler. I Tepler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Tepler, I, et al.. (1999). Low-dose vincristine-associated bilateral vocal cord paralysis.. PubMed. 63(10). 583–4. 7 indexed citations
2.
Seidman, Andrew D., Clifford A. Hudis, J. Albanell, et al.. (1998). Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.. Journal of Clinical Oncology. 16(10). 3353–3361. 318 indexed citations
3.
Seidman, Andrew D., C. Hudis, John McCaffrey, et al.. (1997). Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.. PubMed. 24(5 Suppl 17). S17–72. 17 indexed citations
4.
Churchill, W. H., Colin A. Sieff, Lawrence N. Shulman, et al.. (1995). The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high‐dose chemotherapy support. Transfusion. 35(10). 837–844. 7 indexed citations
5.
Elias, Alby, Lois Ayash, Catherine Wheeler, et al.. (1995). Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.. PubMed. 15(3). 373–9. 32 indexed citations
6.
Tepler, I, Anthony Elias, Leslie A. Kalish, et al.. (1994). Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression. British Journal of Haematology. 87(4). 678–686. 14 indexed citations
7.
Ayash, Lois, Anthony Elias, Catherine Wheeler, et al.. (1994). Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.. Journal of Clinical Oncology. 12(1). 37–44. 117 indexed citations
8.
Elias, Anthony, C Wheeler, I Tepler, et al.. (1994). High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.. PubMed. 21(5 Suppl 12). 83–5. 4 indexed citations
9.
Antman, Karen H., Lois Ayash, Anthony Elias, et al.. (1994). High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.. PubMed. 91–4. 6 indexed citations
10.
Elias, Anthony, Lois Ayash, I Tepler, et al.. (1993). The Use of G-CSF or GM-CSF Mobilized Peripheral Blood Progenitor Cells (PBPC) Alone or to Augment Marrow as Hematologic Support of Single or Multiple Cycle High-Dose Chemotherapy. Journal of Hematotherapy. 2(3). 377–382. 8 indexed citations
11.
Tepler, I, S A Cannistra, Emil Frei, et al.. (1993). Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.. Journal of Clinical Oncology. 11(8). 1583–1591. 67 indexed citations
12.
Elias, Anthony, Lois Ayash, Emil Frei, et al.. (1993). Intensive Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 85(7). 559–566. 44 indexed citations
13.
Elias, Anthony, Rosemary Mazanet, Kenneth C. Anderson, et al.. (1992). GM-CSF mobilized peripheral blood stem cell autografts: The DFCI/BIH experience. Stem Cells. 10(S1). 149–151. 5 indexed citations
14.
15.
16.
Pattengale, P K, Timothy A. Stewart, A Leder, et al.. (1989). Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes.. PubMed. 135(1). 39–61. 76 indexed citations
17.
Tepler, I, Akira Shimizu, & Philip Leder. (1989). The Gene for the Rat Mast Cell High Affinity IgE Receptor α Chain. Journal of Biological Chemistry. 264(10). 5912–5915. 25 indexed citations
18.
Tepler, I, Cynthia C. Morton, Akira Shimizu, et al.. (1989). The gene for the human mast cell high-affinity IgE receptor alpha chain: chromosomal localization to Iq21-q23 and RFLP analysis.. PubMed. 45(5). 761–5. 10 indexed citations
19.
Shimizu, Akira, I Tepler, Philip N. Benfey, et al.. (1988). Human and rat mast cell high-affinity immunoglobulin E receptors: characterization of putative alpha-chain gene products.. Proceedings of the National Academy of Sciences. 85(6). 1907–1911. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Novarino Breakdown of academic impact, for papers by Mark A. Arnesen Breakdown of academic impact, for papers by M. Luisa Paccagnella Breakdown of academic impact, for papers by Manfred Hensel Breakdown of academic impact, for papers by Monica Astolfi Breakdown of academic impact, for papers by Diane C. Louie Breakdown of academic impact, for papers by C. Faul Breakdown of academic impact, for papers by PM Kluin Breakdown of academic impact, for papers by Rosemary Mazanet Breakdown of academic impact, for papers by Martin D. Phillips
Rankless by CCL
2026